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Abstract 
 
Over the last few years, both synchrotron-based FTIR (S-FTIR) and Raman 
microspectroscopies have helped to better understand the effects of drugs on cancer 
cells. However, cancer is a mixture of cells with different sensitivity/resistance to 
drugs. Furthermore, the effects of drugs on cells produce both chemical and 
morphological changes, the latter could affect the spectra of cells incubated with 
drugs. Here, we successfully cloned sensitive and resistant leukaemia cells to 
nilotinib, a drug used in the management of leukaemia. This allowed both the study 
of a more uniform population and the study of sensitive and resistant cells prior to 
the addition of the drug with both S-FTIR and Raman microspectroscopies. The 
incubation with nilotinib produced changes in the S-FTIR and Raman spectra of both 
sensitive and resistant clones to nilotinib. Principal Component Analysis was able to 
distinguish between cells incubated in the absence or presence of the drug, even in 
the case of resistant clones. The latter would confirm that the spectral differences 
between the so-called resistant clonal cells prior to and after adding a drug might 
reside on those more or less sensitive cells that have been able to remain alive when 
they were collected to be studied with S-FTIR or Raman microspectroscopies. The 
data presented here indicate that the methodology of cell cloning can be applied to 
different types of malignant cells. This should facilitate the identification of spectral 
biomarkers of sensitivity/resistance to drugs. The next step would be a better 
assessment of sensitivity/resistance of leukaemia cells from patients which could 
guide clinicians to better tailor treatments to each individual patient. 
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Introduction 
 
Chronic myelogenous leukaemia (CML), a bone marrow stem cell disease, accounts 
for approximately 10%-15% of all leukaemia cases. The reciprocal translocation 
between chromosomes 22 and 9 allows the generation of the chimeric bcr-abl fusion 
gene, the so-called Philadelphia chromosome. This acquired genetic aberration can 
be observed in 95% of CML patients1. The molecular defect resides in the abnormal 
tyrosine kinase activity of the kinase domain in the resulting bcr-abl protein. As a 
consequence, downstream target proteins become hyper-phosphorylated and their 
homeostatic control is undermined allowing stem cell growth to become independent 
of the action of cell growth factors and insensitive to pro-apoptotic stimuli. The 
outcome is both increased cell proliferation and resistance to apoptosis of CML stem 
cell population which progressively expands in the bone marrow2, 3. These features 
make the kinase domain of bcr-abl protein an important target in the development of 
anti-leukaemic drugs which include amongst others imatinib, nilotinib and dasatinib4. 
Imatinib was the first to be developed and this leading compound still represents the 
first choice in the treatment of CML patients. However, drug-resistance is a problem. 
Therefore, great efforts are being placed to develop new tyrosine kinase inhibitor 
(TKI) molecules in an attempt to induce cytogenetic remission and/or delay the onset 
of drug-resistance in CML patients. 
 
Presently, the therapeutic follow-up of CML makes use of available clinical laboratory 
tests that quantify residual disease in CML patients5. The kinase domain mutation 
analysis allows to predict/assess cancer cells’ sensitivity/resistance to anti-leukaemic 
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drugs6. However, there are still two major issues in the management of leukaemia. 
First, the anti-leukaemic strategy is mainly based on protocols tested in multicentre 
studies and, at present, it is not possible to establish “a priori” the best drug and/or 
combination of drugs for each individual patient. Second, the systematic analysis of 
abl kinase domain mutations is not a reliable and economically convenient approach 
to ascertain what tumour cell clones will develop drug resistance. In fact, the 
Philadelphia chromosome is characterized by its intrinsic hyper-mutability allowing 
the monitoring of kinase domain mutations most likely unfeasible7. In addition, there 
is high phenotypic variability within cells of a given tumour and leukaemic clones will 
contain sub-clones with different unpredictable grades of sensitivity/resistance to 
TKIs8. 
 
Vibrational microspectroscopy has been applied to study leukaemia cells’ 
sensitivity/resistance to drugs in vitro9-21 and to assess/monitor therapeutic 
responses in patients with leukaemia22-24. All these studies have proven that 
vibrational spectroscopy, performed either with FTIR or Raman techniques, is 
sensitive enough to identify some biochemical signatures related to the effects of 
different anti-leukemic drugs. However, one of the limitations of those studies is that 
most probably the presence of both drug-sensitive and drug-resistant cell clones and 
all the possible variations in-between in those samples was not appropriately taken 
into account. The uncertainty regarding the relative fractions of sensitive and 
resistant cells in the sample can limit the results’ interpretation, in particular when the 
IR spectra are an average of signals from cells with different phenotypes16. 
Therefore, it is important when assessing cell sensitivity/resistance to drugs using 
vibrational spectroscopy to be carried out with samples containing cells with a 
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uniform phenotype25. Cell sub-cloning is a recently applied strategy to explore the 
infrared identification of gemcitabine-sensitivity/resistance in more cell homogeneous 
samples exposed to a drug26.  
 
The present work aims at assessing whether combining cell sub-cloning and 
principal component analysis (PCA) of both FTIR and Raman spectra datasets is an 
appropriate approach that could be extended to test and predict drug-
resistance/sensitivity in leukaemic cells. Leukaemia is thus an excellent example to 
assess this methodology with a clinical application thanks to the ease of obtaining 
leukemia cells from the peripheral blood of CML patients. In order to identify possible 
spectral markers of sensitivity/resistance, chronic myelogenous leukaemia cell 
clones were analysed prior to and after the addition of nilotinib. Both, synchrotron 
based FTIR (S-FTIR) and Raman microspectroscopy were used in this study. 
Nilotinib is an effective second generation TKI molecular compound developed to 
overcome imatinib resistance in leukaemic cells27, 28 and showing greater efficacy 
than imatinib29. However, some leukaemia cells still display significant resistance to 
nilotinib30. 
 
Materials and Methods 
 
Cell line 
The K562 chronic myelogenous leukaemia cell line, a widespread model of human 
CML utilized for the ex vivo testing/screening of drugs, was used in this study. Cells 
were grown in suspension in RPMI 1640 culture medium supplemented with 10% 
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Foetal Bovine Serum, 1% L-Glutamine, 1% Hepes Buffer, and 1% 
Antibiotic/antimycotic (complete medium) in culture flasks (Sarstedt, UK) at 37°C and 
5% CO2. The growth medium was changed every 3-4 days and cells were split 1:3. 
Cell viability was determined with the standard trypan blue exclusion method. 
 
Cell cloning 
Cells were expanded in 75 cm2 culture flasks (Sarstedt, UK), transferred to 50 mL 
conical tubes and centrifuged at 950 rpm for 3 minutes. The supernatant was 
discarded and the cell pellet was dislodged and re-suspended in fresh complete 
medium. Cells were then counted using the trypan blue exclusion assay. Living cells 
were appropriately diluted in complete medium and seeded in flat-bottomed 96 well 
plates at a concentration of 0.5 cells/200 μL/well (example and for simplicity, for 100 
wells, 50 cells were placed in 20 mL of medium and distributed evenly in these 100 
wells). The plates were incubated at 37°C and in a 5% CO2 atmosphere. Following 
one week culture, the plates were spun at 1200 rpm for 7 minutes. Following this, 
100 μL of medium were removed and 100 μL of fresh complete medium were added. 
Plates were further incubated at 37°C and 5% CO2 for one week to allow the clones 
to develop. Clones were inspected regularly so those wells with more than 1 clone 
could be discarded. After these 2 weeks culture, between 15 and 20 clones grew per 
each 96 well plate. In order to study as many cells as possible for each individual 
clone, especially those grown in the presence of nilotinib, the number of cells for 
each individual clone were not counted. 
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Nilotinib 
Nilotinib (a kind gift of Novartis, Switzerland) was provided in powder form (100 mg) 
and dissolved in DMSO to a final concentration of 10 mM according to the provider’s 
instructions. Aliquots were stored at -20 °C. Nilotinib was added to cells as follows. 
After 2 weeks culture in 96 well plates as described above, clones were collected by 
gently mixing the media in each individual well containing an individual clone and 
collecting both the total media (200 µL) and cells. For each individual clone, cells 
were seeded proportionally in 3 wells in 96 flat-bottomed plates. They were allowed 
to grow for a further 24 hours at 37 °C and 5% CO2. Following this incubation period, 
plates were spun at 1200 rpm for 7 minutes. Following this, 100 µL of growth 
medium were removed and 100 µL of fresh medium with different concentrations of 
nilotinib were added (final concentrations of 0 µM, 50 µM or 100 µM). Cells were 
then allowed to grow for 5 days at 37 °C and 5% CO2 in order to assess clone cell 
growth. Preliminary work was carried out to optimise time-course and dose-response 
experiments with nilotinib. It was observed that keeping cells growing for more than 5 
days translated into cells overgrowing in control wells (in the presence of 0 µM 
nilotinib). On the other hand, clones grew in the presence of 10 µM nilotinib, and all 
clones died at 5 days culture in the presence of 500 µM nilotinib. Therefore, the 
doses of 0 µM, 50 µM and 100 µM nilotinib and an incubation time of 5 days were 
established in this study. In order to assess cell survival in the absence or presence 
of nilotinib which decreases cell viability in a time, dose and growth condition 
dependent manner, clones that grew to confluence (cells occupied the whole surface 
of the well) were labelled “++” and those clones that grew to semi-confluence (cells 
did not occupy the whole surface of the well) were labelled “+”. Wells that contained 
just few cells were labelled “+/-”. Finally, those wells which contained no cells were 
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labelled “-.” Table I shows a representative example of clones obtained from one 96 
well plate. 
 
Vibrational Microspectroscopy 
Sample preparation. Following cell incubation in the absence or presence of nilotinib, 
cells were collected, transferred into Eppendorf tubes and centrifuged at 950 rpm for 
3 minutes at room temperature. Supernatant was then removed and the pelleted 
cells were re-suspended in 0.9% NaCl. Cells were then cytospun on CaF2 slides for 
1 minute at 550 rpm and fixed with 4% buffered paraformaldehyde in 0.9% NaCl for 
20 min at room temperature. Excess formalin was removed by washing once with 
NaCl 0.9% and thrice rinsed with distilled water. Samples were then air dried at room 
temperature31. UV graded CaF2 slides (26 x 22 x 0.5 mm) (Crystan Ltd, UK) suitable 
for both FTIR and Raman microspectroscopy were used. Spectra of 50 individual 
cells were obtained from control and nilotinib-resistant clones while this number was 
reduced in samples that resulted sensitive to nilotinib (see Figures’ legends). 
 
S-FTIR microspectroscopy. S-FTIR spectra were recorded in transmission mode at 
MIRIAM beamline at Diamond Light Source, UK. The end station has a Hyperion 
3000 microscope (Bruker) with a liquid nitrogen cooled 50 µm pitch high sensitivity 
MCT detector coupled to a Bruker 80V FTIR spectrometer. Opus (Bruker) software 
was used to record the FTIR spectra (and visible images) at 4 cm-1 resolution with 
256 co-added scans. Based on our previous work31, single cell IR data were taken in 
transmission mode using 15×15 μm slits via a 36x objective/condenser optics and 
centring onto the cell nucleus. 
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Pre-processing. IR spectra were corrected for baseline fluctuation using non-
resonant Mie scattering extended multiplicative signal correction (EMSC)32. 
Following EMSC correction, the spectra were cropped to the fingerprint (1000-1800 
cm-1) and the lipid (2700–3100 cm-1) regions and normalized using standard normal 
variate (SNV), which subtracts the mean spectrum and then divides by the standard 
deviation for each spectrum removing the effect of different sample thickness and 
spectrum baseline offsets. Afterwards, principal component analysis (PCA) was 
performed using Unscrambler X software (CAMO).  
 
Raman spectroscopy. A Senterra Raman (Bruker) system was used off line at 
MIRIAM beamline at Diamond Light Source, equipped with 532 nm 100 mW laser 
and a Si CCD detector thermoelectrically cooled at -80 °C. Opus (Bruker) software 
was used to obtain the Raman microspectra and visible images via a 100x 0.8 NA 
low-fluorescence objective, with internal Neon lamp for spectral calibration. The 
spectra were recorded between 40 and 4450 cm-1 at resolution 9-18 cm-1 by co-
adding 2 acquisitions (for cosmic ray removal) each of 10 seconds integration time. 
A 50 µm pinhole and total power of max 10 mW was used at the spectrograph 
entrance, in order to guarantee confocality and detectable Raman signal below the 
damaging threshold of the sample. Three spectra were recorded on different 
locations of each individual cell and averaged. Rubberband baseline correction was 
carried out followed by SNV normalization. PCA was performed using Unscrambler. 
As in the case of S-FTIR microspectra, Raman microspectra were obtained from the 
nuclear area based on our previous work showing that differences between cells 
reside mainly in the nucleus31, 33. For each clone, Raman spectra of 50 individual 
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control cells were obtained. Spectra of 50 individual cells were obtained from control 
and nilotinib-resistant clones while this number was reduced in samples that resulted 
sensitive to nilotinib (see Figures’ legends). 
 
RESULTS 
 
The aim of this feasibility study was to identify possible IR and/or Raman spectral 
markers of nilotinib sensitivity/resistance in a clonal leukaemia cell population. 
Furthermore, sensitive and resistant clone cells were studied prior to the addition of 
the drug in order to obviate any morphological changes related to the pro-apoptotic 
effects of nilotinib that could affect their IR and/or Raman spectra. The beamtime at 
MIRIAM beamline was mainly dedicated to the study of the effects of nilotinib in 
clonal cells using S-FTIR microspectroscopy. We also took the opportunity to 
complement this work with Raman studies on the effects of nilotinib on clonal 
leukaemia cells. 
 
The cloning of the K562 cell line yielded between 15 and 20 cell clones with different 
sensitivities to nilotinib per each 96 well plate. Table I shows a representative 
example of the clones obtained from a 96 well plate. It is obvious that even within an 
already well established cell line there are important phenotypical differences in the 
sensitivity/resistance of individual cells to nilotinib. This tumour variability could mask 
some of the spectral markers of cell sensitivity to a given drug if the spectra were 
taken from a mixed cell culture containing a higher number of resistant cells. 
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Following cell cloning and incubation with nilotinib, we studied the effects of nilotinib 
in a cell clone resistant to both 50 µM and 100 µM nilotinib i.e., at least 50 cells could 
be studied for each of the three doses of nilotinib (0 µM, 50 µM and 100 µM). We 
also chose a clone sensitive to 100 µM of nilotinib and semi-sensitive to 50 µM of 
nilotinib (only 23 cells could be studied when the cell clone was incubated with 50 
µm of nilotinib). Figure 1 shows the mean spectra for clone 4F (resistant to both 50 
µM and 100 µM of nilotinib). Even in a resistant clone, there are spectral changes 
following the addition of nilotinib. The differences reside mainly in the shape of the 
amide I and II bands (becoming broader following the addition of the drug) and a 
decrease in the intensity of the peaks at 1740 cm-1, 2850 cm-1 and 2920 cm-1. In the 
case shown in Figure 2, clone 7F (semisensitive/semiresistant to nilotinib) has again 
a broadening of the amide I and II bands. Here, there is a small increase in the 
intensity of the peaks at 1740 cm-1, 2850 cm-1, and 2920 cm-1.  
 
PCA of these 2 clones prior to and after the addition of nilotinib and corresponding 
plots can be seen in Figures 3 and 4 respectively. As can be seen in Figure 3, even 
in a resistant clone, some separation between control cells and those incubated with 
the drug could be seen both in the fingerprint and the lipid regions. More importantly, 
the separation was higher for the semisensitive/semiresistant clone between control 
cells and those cells incubated with 50 µM nilotinib. 
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On the other hand, the PCA of control cells (incubated with 0 µM nilotinib) for 
resistant and sensitive clones is shown in Figure 5. These clones are: resistant 
clones 2F, 3F and 4F to both 50 µM and 100 µM of nilotinib (crosses); sensitive 
clone 1F to both 50 µM and 100 µM nilotinib (filled triangles) and sensitive clones 5F 
and 7F to 100 µM nilotinib only (open circles). As can be seen in Figure 5, there was 
a clear separation between the control cells for the resistant clones and the control 
cells for the clone sensitive to both 50 µM and 100 µM nilotinib for both fingerprint 
and lipid regions. Furthermore, there was also some separation between control 
cells for resistant clones to both 50 µM and 100 µM of nilotinib and control cells for 
clones sensitive to 100 µM nilotinib only for both fingerprint and lipid regions. 
 
Raman spectra of a resistant and a semiresistant/semisensitive clone were also 
obtained. Figure 6 shows the mean spectra of resistant clone 1Ra cells (resistant to 
both 50 µM and 100 µM of nilotinib) in the absence and in the presence of nilotinib at 
50 µM and 100 µM. No major differences can be seen between control cells 
(incubated with 0 µM nilotinib) and cells incubated with 50 µM nilotinib apart from a 
decrease in the intensity of the peak at 1100 cm-1. However, some changes can be 
seen in cells incubated with 100 µM nilotinib. These differences are mainly an 
increase in the intensity of the peaks at 965 cm-1 and 1610 cm-1. On the other hand, 
Figure 7 shows the mean spectra of semiresistant/semisensitive clone 2Ra. In this 
case, only 25 cells could be seen following the incubation with 50 µM of nilotinib. 
Here, the main differences were a change in the ratios of peaks at 1315 cm-1 and 
1335 cm-1, and a decrease in the intensity of the peaks at 780, 1100, 1370, 1485, 
1520 and 1580 cm-1. Figures 8 and 9 show the PCA and corresponding plots prior to 
and after the addition of nilotinib for these 2 clones, respectively. It can be seen in 
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Figure 8 that even for resistant clones, a separation between control cells and those 
incubated with either 50 µM or 100 µM nilotinib could be seen. Furthermore, a clear 
separation could be observed between control cells and those incubated with 50 µM 
nilotinib for the semiresistant/semisensitive clone 2Ra cells (Figure 9). 
 
DISCUSSION 
 
The potential of vibrational spectroscopy as a tool which could help in the 
management of leukaemia to better tailor treatment to an individual patient is widely 
accepted based on the number of publications on the subject (see Introduction). 
However, before this technique makes it into clinical practice, a better understanding 
of tumour cell sensitivity/resistance to drugs is needed. Leukaemia, like solid 
tumours, is made up of a whole array of resistant/sensitive cells to different drugs 
and combinations of drugs. One way to have a better understanding of the 
percentage of resistant or sensitive cells to a given drug in a whole leukaemia 
population is to carry out cell cloning and use this methodology together with 
vibrational spectroscopy to assess the presence of spectral biomarkers of 
resistance/sensitivity to the drug. While we have already shown the proof of concept 
in lung cancer26, it was important to us to assess whether the same methodology 
could also be applied to a different type of tumour such as leukaemia, and using a 
drug with a different mechanism of action (nilotinib). Table I not only gives a 
representative example of the feasibility of this methodology in leukaemia but also 
gives an indication of the number of resistant, semiresistant/semisensitive and 
sensitive clones to nilotinib that are present in a whole leukaemia cell population. 
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This clearly indicates that the studies of the effects of drugs in whole cancer cell 
populations might prove more difficult to identify possible spectral biomarkers of 
resistance/sensitivity to drugs due to cellular heterogeneity. Cell cloning could be a 
way to more easily characterise the possible presence of these spectral biomarkers 
in a cancer cell population. 
 
The data presented here shows that even in the so-called resistant clones (resistant 
to both 50 µM and 100 µM of nilotinib) some differences can be seen when carrying 
out PCA (Figure 3). It has to be taken into account that, even in a resistant cell 
population, following the incubation with the drug, there will be cells that could have 
been damaged, and might be repairing this damage or entering the initial phase of 
apoptosis (programmed cell death). It could be hypothesised that the differences 
seen here in the resistant clone following the addition of nilotinib at 50 µM or 100 µM 
could be caused by the presence of these damaged cells that were still alive when 
the sample was collected to carry out S-FTIR or Raman microspectroscopy. 
Obviously, further work is needed to confirm this. 
 
The main differences seen in the S-FTIR spectra of semiresistant/semisensitive cells 
was an increase in the intensity of the peaks at 2850 cm-1 and 2920 cm-1 
corresponding mainly to CH2 stretching modes of methylene chains in membrane 
lipids and the peak at 1740 cm-1 arising from the carbonyl C=O stretching mode of 
phospholipids34, 35. We and others have described this increased intensity in the lipid 
peaks following the addition of drugs to different cell types18, 19, 26, 36-38 which could be 
a spectral marker of apoptosis as an increase in lipid content correlates with 
15 
 
apoptosis12, 38, 39. On the other hand, the intensity of these 3 peaks decreased 
following the addition of the drug to resistant cell clones (Figure 1). This is in 
agreement with previously reported data indicating an association between a 
decrease in lipids and drug resistance both in cell lines and in cells freshly isolated 
from leukemia patients40. However, it has also been described that there is a slight 
increase in intensity in the bands at 2854 cm-1 and 1740 cm-1 in imatinib resistant 
K562 leukaemia cells20, an increase in the amount of unsaturated lipids in nilotinib 
resistant K562 cells17 and a decrease in the intensity of the 1740 cm-1 band in 
imatinib sensitive K562 cells21. It is difficult to assess whether these reported results 
are different due to the fact that whole leukaemia cell populations were studied 
and/or resistant cell lines were created prior to studying the effects of drugs rather 
than studying the effects of a drug on a given clonal cell population. Furthermore, it 
has been described that some cells may have different rates of drug response 
indicating that not all drug exposed cells show a change in their spectra at a given 
incubation time15. This stresses the importance of studying a homogeneous cell 
population such as cell clones, to better assess possible spectral biomarkers of cell 
sensitivity/resistance to drugs.  
 
Another important change in our cell clones following the addition of nilotinib was the 
decreased intensity and changes in the amides’ region even for resistant cells 
(Figures 1 and 2). Changes in this region following the addition of drugs to leukaemia 
cells have also been previously reported10, 14, 36, 41. An important consideration in the 
study of cancer cells and their sensitivity to drugs would be to identify cell 
populations that could be sensitive or resistant to drugs prior to the addition of the 
drug. The data presented here (Figure 5) indicate that it is possible to separate, to a 
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certain extent, between nilotinib sensitive and resistant leukaemia cell clones. This 
was not the case in our previous work where no differences were seen between 
sensitive and resistant lung cancer cells clones26. However, it has to be taken into 
account that the differences might simply be due to the fact these are different 
clones. Further work is needed to assess whether different cell types could have 
different spectral markers of cell sensitivity to drugs. 
 
On the other hand, Raman spectroscopy was also able to separate between cell 
clones in the absence or presence of nilotinib (Figure 6 and 7). For the sensitive cell 
clone, the main differences resided in an increase in the peak at 1335 cm-1 (CH 
vibrations)42, 43, and a decrease in the peaks at 1370, 1485, 1520 cm-1 (all three due 
to adenine)44. However, for the resistant cell clone, while no major differences were 
seen between control cells (incubated with 0 µM nilotinib) and cells incubated with 50 
µM nilotinib, there were differences when these cells were compared to cells 
incubated with 100 µM nilotinib, mainly at peaks 960 cm-1 (vibrational mode of 
proteins)45, and 1610 cm-1 (tyrosine)44. The reason why changes in lipids were 
mostly seen when using FTIR microspectroscopy could be due to the way the 
experiments were implemented. In the case of FTIR microspectroscopy, the cell area 
covered was 15 x 15 µm while for Raman microspectroscopy was around 1 µm and 
focussed on the cell nucleus. An aperture of 15 x 15 µm would include most if not all 
of the cell and, thus, membrane lipids (with their corresponding changes mentioned 
above after the addition of the drug) while this would not be the case in Raman 
microspectroscopy. On the other hand, the spectral changes linked to DNA 
(decrease in the intensity of the adenine peaks in Raman and a decrease of the 
intensity of the peaks at 1080 cm-1 and 1240 cm-1 in FTIR) are due most probably to 
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apoptosis. It is well known that apoptosis causes nuclear fragmentation, membrane 
blebbing and release of apoptotic bodies leading, amongst other, to changes in cells’ 
DNA. In fact, nilotinib not only binds to bcr-abl protein but also inhibits a broad 
spectrum of protein kinases which leads to apoptosis in several tumour cells 
including K562 leukaemia cells46. 
 
The data presented here indicate that the methodology of cell cloning can be applied 
to different types of malignant cells. Furthermore, it could represent a way forward to 
study the effects of drugs on more uniform cell populations. This should facilitate the 
identification of spectral biomarkers of sensitivity/resistance to drugs which otherwise 
could be partially masked in more heterogeneous cell populations. Further steps are 
needed to better understand how possible spectral biomarkers present in different 
cell clones correlate with a mode of death and/or different phases within the 
apoptosis process. The final aim would be to assess sensitivity/resistance of 
leukaemia cells from patients to better tailor treatment to each individual patient. 
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Legends to Figures 
 
Figure 1. S-FTIR spectra of clone 4F (resistant to both 50 µM and 100 µM of 
nilotinib) in the presence and absence of nilotinib. Each spectrum is the 
mean of 50 individual spectra from 50 individual cells. Spectra are offset 
for clarity. 
 
Figure 2. S-FTIR spectra of clone 7F (partially sensitive to 50 µM of nilotinib) in the 
presence and absence of nilotinib. The spectra are the mean of 50 
individual spectra from 50 individual cells (0 µM) and the mean of 23 
individual spectra from 23 individual cells (50 µM). Spectra are offset for 
clarity. 
 
Figure 3. PCA of FTIR spectra of clone 4F (resistant to both 50 and 100 µM of 
nilotinib) for cells incubated with 0 µM nilotinib (circles), 50 µM nilotinib 
(triangles), and 100 µM nilotinib (crosses) for fingerprint (A) and lipid (C) 
regions and loading plots, respectively (B and D).  
 
Figure 4. PCA of FTIR spectra of clone 7F (partially sensitive to 50 µM of nilotinib) 
for cells incubated with 0 µM nilotinib (circles) and 50 µM nilotinib 
(triangles) for (fingerprint (A) and lipid (C) regions and loading plots, 
respectively (B and D). 
 
Figure 5. PCA of FTIR spectra of control cells (incubated with 0 µM nilotinib) of 
sensitive and resistant study clones for fingerprint (A) and lipid (C) regions 
and loading plots, respectively (B and D). See main text for data labelling. 
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Figure 6. Raman spectra of clone 1Ra (resistant to both 50 µM and 100 µM of 
nilotinib) in the presence and absence of nilotinib. Each spectrum is the 
mean of 50 individual spectra from 50 individual cells. Spectra are offset 
for clarity. 
 
Figure 7. Raman spectra of clone 2Ra (partially sensitive to 50 µM of nilotinib) in 
the presence and absence of nilotinib. The spectra are the mean of 50 
individual spectra from 50 individual cells (0 µM) and the mean of 25 
individual spectra from 25 individual cells (50 µM). Spectra are offset for 
clarity. 
 
Figure 8. PCA of Raman spectra (A) and loading plot (B) of clone 1Ra (resistant to 
both 50 µM and 100 µM of nilotinib) for cells incubated with 0 µM nilotinib 
(circles), 50 µM nilotinib (triangles), and 100 µM nilotinib (crosses).  
 
Figure 9. PCA of Raman spectra (A) and loading plot (B) of clone 2Ra (partially 
sensitive to 50 µM of nilotinib) for cells incubated with 0 µM nilotinib 
(circles) and 50 µM nilotinib (triangles). 
 
24 
 
 
 
 
 
 
  
25 
 
 
 
 
  
26 
 
 
 
 
  
27 
 
 
 
 
  
28 
 
 
 
 
 
 
  
29 
 
 
 
 
 
  
30 
 
 
 
 
 
  
31 
 
 
 
 
  
32 
 
 
 
 
 
  
33 
 
 
 
 
 
  
34 
 
 
 
 
  
35 
 
 
 
 
  
36 
 
 
 
 
 
  
37 
 
 
 
 
 
  
38 
 
 
 
 
 
  
39 
 
 
 
 
 
  
40 
 
 
 
 
 
  
41 
 
 
 
 
  
42 
 
 
 
 
 
  
43 
 
 
 
 
 
  
44 
 
Table I: Representative example of K562 cell clones following 5 days 
incubation with nilotinib at different doses. 
 
Clones Control (0 µM) 50 μM 100 μM 
1 ++ +/- +/- 
2 ++ + ++ 
3 ++ + +/- 
4 ++ + + 
5 ++ + + 
6 ++ + + 
7 ++ + + 
8 ++ + + 
9 ++ + + 
10 ++ + + 
11 ++ + +/- 
12 ++ + + 
13 +- +/- +/- 
14 ++ +/- +/- 
15 ++ + + 
16 ++ +/- - 
17 ++ +/- +/- 
18 ++ +/- - 
 
 
